When treating lung cancer, there’s one elusive mutation that can rear its ugly head: Exon 20. The Hydra campaign illustrates the threat of EXON 20 mutations in advanced NSCLC, and how there is a lack of effective options for these patients. It also informs oncologists that multi-mechanistic approaches are being explored that are designed to reign in this elusive and uncontrolled menace.